Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Cardiotoxicity 14Breast Neoplasms 11Lymphoma, Non-Hodgkin 5Neoplasms 4Lymphoma 4Heart Failure 4Prostatic Neoplasms 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia 2Heart Diseases 2Cardiovascular Diseases 2Burkitt Lymphoma 2Ventricular Dysfunction, Left 1Ventricular Dysfunction 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Obesity 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1Mesothelioma 1Memory Disorders 1

Interventions

Cyclophosphamide 346Cytarabine 282fludarabine phosphate 203Methotrexate 186Filgrastim 159Busulfan 148Etoposide 135Peripheral Blood Stem Cell Transplantation 134fludarabine 128Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 86Mycophenolic Acid 86Whole-Body Irradiation 81Melphalan 79Imatinib Mesylate 69Idarubicin 67Granulocyte Colony-Stimulating Factor 66Mercaptopurine 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × Echocardiography × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡